2,820
Views
3
CrossRef citations to date
0
Altmetric
Oncology

The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada

, , , ORCID Icon &
Pages 150-161 | Received 23 Oct 2020, Accepted 21 Dec 2020, Published online: 01 Feb 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.